Citius Oncology (CTOR) Receivables - Net (2025 - 2026)

Citius Oncology (CTOR) posted quarterly Receivables - Net of $1.1 million for Q1 2026, down 73.35% quarter-over-quarter from $4.0 million in Q4 2025.

Citius Oncology (CTOR) Receivables - Net (2025 - 2026) Analysis & Trends

Citius Oncology (CTOR) has reported Receivables - Net for 2 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	Citius Oncology	80.25 Mn	80.25 Mn	1.00 Mn

Download Data